Nothing Special   »   [go: up one dir, main page]

SG11202102985YA - Protein tyrosine phosphatase inhibitors - Google Patents

Protein tyrosine phosphatase inhibitors

Info

Publication number
SG11202102985YA
SG11202102985YA SG11202102985YA SG11202102985YA SG11202102985YA SG 11202102985Y A SG11202102985Y A SG 11202102985YA SG 11202102985Y A SG11202102985Y A SG 11202102985YA SG 11202102985Y A SG11202102985Y A SG 11202102985YA SG 11202102985Y A SG11202102985Y A SG 11202102985YA
Authority
SG
Singapore
Prior art keywords
protein tyrosine
tyrosine phosphatase
phosphatase inhibitors
inhibitors
protein
Prior art date
Application number
SG11202102985YA
Inventor
James F Blake
Mark Laurence Boys
Mark Joseph Chicarelli
Adam Cook
Mohamed S A Elsayed
Jay B Fell
John P Fischer
Ronald Jay Hinklin
Oren T Mcnulty
Macedonio J Mejia
Martha E Rodriguez
Christina E Wong
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of SG11202102985YA publication Critical patent/SG11202102985YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11202102985YA 2018-10-17 2019-10-17 Protein tyrosine phosphatase inhibitors SG11202102985YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746952P 2018-10-17 2018-10-17
US201962916119P 2019-10-16 2019-10-16
PCT/US2019/056786 WO2020081848A1 (en) 2018-10-17 2019-10-17 Protein tyrosine phosphatase inhibitors

Publications (1)

Publication Number Publication Date
SG11202102985YA true SG11202102985YA (en) 2021-05-28

Family

ID=68536896

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102985YA SG11202102985YA (en) 2018-10-17 2019-10-17 Protein tyrosine phosphatase inhibitors

Country Status (27)

Country Link
US (1) US20210380582A1 (en)
EP (1) EP3867238B1 (en)
JP (1) JP7449282B2 (en)
KR (1) KR102649419B1 (en)
CN (1) CN114341124B (en)
AU (1) AU2019359885B2 (en)
BR (1) BR112021005733A2 (en)
CA (1) CA3116561C (en)
CL (1) CL2021000972A1 (en)
CO (1) CO2021004966A2 (en)
CR (1) CR20210189A (en)
CU (1) CU20210029A7 (en)
CY (1) CY1126122T1 (en)
DO (1) DOP2021000070A (en)
EC (1) ECSP21027049A (en)
ES (1) ES2947464T3 (en)
HU (1) HUE062404T2 (en)
IL (1) IL282179B2 (en)
MA (1) MA53921A (en)
MX (1) MX2021004410A (en)
NI (1) NI202100027A (en)
PE (1) PE20211465A1 (en)
PH (1) PH12021550674A1 (en)
PL (1) PL3867238T3 (en)
SG (1) SG11202102985YA (en)
WO (1) WO2020081848A1 (en)
ZA (1) ZA202101960B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018057884A1 (en) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TWI848901B (en) 2016-10-24 2024-07-21 美商傳達治療有限公司 Shp2 phosphatase inhibitors and methods of use thereof
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
US20220315586A1 (en) 2018-03-21 2022-10-06 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
JP7284830B2 (en) 2019-04-02 2023-05-31 アレイ バイオファーマ インコーポレイテッド protein tyrosine phosphatase inhibitor
BR112022005349A2 (en) 2019-09-24 2022-06-14 Relay Therapeutics Inc shp2 phosphatase inhibitors and methods of production and use thereof
KR20220100903A (en) 2019-11-08 2022-07-18 레볼루션 메디슨즈, 인크. Bicyclic heteroaryl compounds and uses thereof
CA3183032A1 (en) 2020-06-18 2021-12-23 Mallika Singh Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
JP2023541916A (en) 2020-09-15 2023-10-04 レボリューション メディシンズ インコーポレイテッド Indole derivatives as RAS inhibitors in the treatment of cancer
TWI825637B (en) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors
AU2022270116A1 (en) 2021-05-05 2023-12-21 Revolution Medicines, Inc. Ras inhibitors
CN117500811A (en) 2021-05-05 2024-02-02 锐新医药公司 Covalent RAS inhibitors and uses thereof
CR20230558A (en) 2021-05-05 2024-01-24 Revolution Medicines Inc Ras inhibitors for the treatment of cancer
CN115340561A (en) * 2021-05-14 2022-11-15 药雅科技(上海)有限公司 Preparation and application of SHP2 phosphatase fused ring inhibitor
TW202244049A (en) * 2021-05-12 2022-11-16 大陸商藥雅科技(上海)有限公司 Preparation and Application of SHP2 Phosphatase Inhibitor
CN115960109B (en) * 2021-05-31 2024-06-25 药雅科技(上海)有限公司 Preparation and application of condensed ring SHP2 phosphatase inhibitor
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
TW202317100A (en) 2021-06-23 2023-05-01 瑞士商諾華公司 Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
WO2023282702A1 (en) 2021-07-09 2023-01-12 주식회사 카나프테라퓨틱스 Shp2 inhibitor and use thereof
KR20240055778A (en) 2021-09-01 2024-04-29 노파르티스 아게 Pharmaceutical combinations comprising TEAD inhibitors and their use for the treatment of cancer
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
TW202346305A (en) * 2022-01-05 2023-12-01 美商雷密克斯醫療公司 Compounds and methods for modulating splicing
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN114621186A (en) * 2022-05-12 2022-06-14 上海维申医药有限公司 Heterocyclic compounds as modulators of RAS signaling pathway
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US20090264426A1 (en) * 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
EP2475666A2 (en) * 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
US9096590B2 (en) * 2010-05-24 2015-08-04 Intellikine Llc Substituted benzoxazoles as PI3 kinase inhibitors
CN105899491B (en) 2014-01-17 2019-04-02 诺华股份有限公司 For inhibiting the active 1- pyridazine-of SHP2/triazine -3- base-piperazine (- piperazine)/pyridine/pyrrolidin derivatives and combinations thereof
ES2699354T3 (en) 2014-01-17 2019-02-08 Novartis Ag Derivatives of 1- (triazin-3-yl / pyridazin-3-yl) -piper (-azin) idine and compositions thereof to inhibit the activity of SHP2
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
ES2741746T3 (en) 2015-06-19 2020-02-12 Novartis Ag Compounds and compositions to inhibit SHP2 activity
CN107922388B (en) 2015-06-19 2020-12-29 诺华股份有限公司 Compounds and compositions for inhibiting SHP2 activity
EP3463343B1 (en) 2016-05-31 2022-03-23 Board of Regents, The University of Texas System Heterocyclic inhibitors of ptpn11
KR102218333B1 (en) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Novel heterocyclic derivatives useful as SHP2 inhibitors
AU2017283769B2 (en) 2016-06-14 2019-08-15 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
TN2019000010A1 (en) 2016-07-12 2020-07-15 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018057884A1 (en) * 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TWI848901B (en) 2016-10-24 2024-07-21 美商傳達治療有限公司 Shp2 phosphatase inhibitors and methods of use thereof
AU2018210770B2 (en) * 2017-01-23 2022-03-24 Revolution Medicines, Inc. Bicyclic compounds as allosteric SHP2 inhibitors
KR20190110588A (en) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. Pyridine Compounds as Allosteric SHP2 Inhibitors
EA202190196A1 (en) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. NEW HETEROCYCLIC DERIVATIVES USED AS SHP2 INHIBITORS
EP3678703A1 (en) 2017-09-07 2020-07-15 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer

Also Published As

Publication number Publication date
IL282179B1 (en) 2024-06-01
MA53921A (en) 2022-01-26
AU2019359885B2 (en) 2024-01-18
CR20210189A (en) 2021-09-14
IL282179A (en) 2021-05-31
CU20210029A7 (en) 2021-11-04
CO2021004966A2 (en) 2021-04-30
PH12021550674A1 (en) 2021-12-13
JP2022504936A (en) 2022-01-13
EP3867238A1 (en) 2021-08-25
NI202100027A (en) 2021-08-24
DOP2021000070A (en) 2021-05-16
ECSP21027049A (en) 2021-05-31
EP3867238B1 (en) 2023-06-07
CY1126122T1 (en) 2023-11-15
WO2020081848A1 (en) 2020-04-23
CN114341124A (en) 2022-04-12
US20210380582A1 (en) 2021-12-09
PL3867238T3 (en) 2023-09-11
CA3116561A1 (en) 2020-04-23
AU2019359885A1 (en) 2021-04-15
JP7449282B2 (en) 2024-03-13
KR102649419B1 (en) 2024-03-21
IL282179B2 (en) 2024-10-01
MX2021004410A (en) 2021-07-06
CA3116561C (en) 2023-09-12
PE20211465A1 (en) 2021-08-05
ES2947464T3 (en) 2023-08-09
BR112021005733A2 (en) 2021-07-27
HUE062404T2 (en) 2023-10-28
CN114341124B (en) 2024-09-20
CL2021000972A1 (en) 2021-10-15
EP3867238C0 (en) 2023-06-07
KR20210076098A (en) 2021-06-23
ZA202101960B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
IL282179A (en) Protein tyrosine phosphatase inhibitors
ZA202108443B (en) Protein tyrosine phosphatase inhibitors
IL283639A (en) Kif18a inhibitors
IL286373A (en) Protein tyrosine phosphatase inhibitor compounds and uses thereof
MA54550A (en) KIF18A INHIBITORS
EP3630783A4 (en) Penicillin-binding protein inhibitors
EP3630782A4 (en) Penicillin-binding protein inhibitors
MA52812A (en) SARM1 INHIBITORS
IL276813A (en) Arginase inhibitors
EP3802551A4 (en) Penicillin-binding protein inhibitors
IL304110A (en) Inhibitors of keap1-nrf2 protein-protein interaction
SG11202010914YA (en) Furin inhibitors
DK3737402T3 (en) Modificeret protein
MA52813A (en) SARM1 INHIBITORS
MA52809A (en) SARM1 INHIBITORS
MA50675A (en) CREB BINDING PROTEIN (CBP) INHIBITORS
IL276013A (en) Pi4kiiibeta inhibitors
ZA201808238B (en) Certain protein kinase inhibitors
EP3555092A4 (en) Protein kinase inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
GB201807845D0 (en) Kinase Inhibitors
EP3345894A4 (en) Compound having protein tyrosine phosphatase shp-1 agonist activity
GB201909710D0 (en) Proteins
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors